A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV
Copyright © 2020 Elsevier Ltd. All rights reserved..
Pulmonary fibrosis (PF) is a lung disease with highly heterogeneous and mortality rate, but its therapeutic options are now still limited. Corona virus disease 2019 (COVID-19) has been characterized by WHO as a pandemic, and the global number of confirmed COVID-19 cases has been more than 8.0 million. It is strongly supported for that PF should be one of the major complications in COVID-19 patients by the evidences of epidemiology, viral immunology and current clinical researches. The anti-PF properties of naturally occurring polysaccharides have attracted increasing attention in last two decades, but is still lack of a comprehensively understanding. In present review, the resources, structural features, anti-PF activities, and underlying mechanisms of these polysaccharides are summarized and analyzed, which was expected to provide a scientific evidence supporting the application of polysaccharides for preventing or treating PF in COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:247 |
|---|---|
| Enthalten in: |
Carbohydrate polymers - 247(2020) vom: 01. Nov., Seite 116740 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Rui-Rong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.09.2020 Date Revised 03.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.carbpol.2020.116740 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314034919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314034919 | ||
| 003 | DE-627 | ||
| 005 | 20231225151848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carbpol.2020.116740 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314034919 | ||
| 035 | |a (NLM)32829859 | ||
| 035 | |a (PII)S0144-8617(20)30913-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Rui-Rong |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A review for natural polysaccharides with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2020 | ||
| 500 | |a Date Revised 03.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Pulmonary fibrosis (PF) is a lung disease with highly heterogeneous and mortality rate, but its therapeutic options are now still limited. Corona virus disease 2019 (COVID-19) has been characterized by WHO as a pandemic, and the global number of confirmed COVID-19 cases has been more than 8.0 million. It is strongly supported for that PF should be one of the major complications in COVID-19 patients by the evidences of epidemiology, viral immunology and current clinical researches. The anti-PF properties of naturally occurring polysaccharides have attracted increasing attention in last two decades, but is still lack of a comprehensively understanding. In present review, the resources, structural features, anti-PF activities, and underlying mechanisms of these polysaccharides are summarized and analyzed, which was expected to provide a scientific evidence supporting the application of polysaccharides for preventing or treating PF in COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Corona virus disease 2019 | |
| 650 | 4 | |a Mechanisms | |
| 650 | 4 | |a Polysaccharides | |
| 650 | 4 | |a Pulmonary fibrosis | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a DANCR long noncoding RNA, human |2 NLM | |
| 650 | 7 | |a FOXO3 protein, human |2 NLM | |
| 650 | 7 | |a Forkhead Box Protein O3 |2 NLM | |
| 650 | 7 | |a HNRNPD protein, human |2 NLM | |
| 650 | 7 | |a Heterogeneous Nuclear Ribonucleoprotein D0 |2 NLM | |
| 650 | 7 | |a Polysaccharides |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a SMAD2 protein, human |2 NLM | |
| 650 | 7 | |a SMAD3 protein, human |2 NLM | |
| 650 | 7 | |a Smad2 Protein |2 NLM | |
| 650 | 7 | |a Smad3 Protein |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta1 |2 NLM | |
| 650 | 7 | |a Bleomycin |2 NLM | |
| 650 | 7 | |a 11056-06-7 |2 NLM | |
| 700 | 1 | |a Li, Ya-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jun-Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Chuan-Li |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Carbohydrate polymers |d 1994 |g 247(2020) vom: 01. Nov., Seite 116740 |w (DE-627)NLM082819491 |x 1879-1344 |7 nnns |
| 773 | 1 | 8 | |g volume:247 |g year:2020 |g day:01 |g month:11 |g pages:116740 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.carbpol.2020.116740 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 247 |j 2020 |b 01 |c 11 |h 116740 | ||